NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

多形性膠質母細胞瘤治療(GBM)的全球市場

Glioblastoma Multiforme Treatment (GBM)

出版商 Global Industry Analysts, Inc. 商品編碼 997634
出版日期 內容資訊 英文 129 Pages
商品交期: 最快1-2個工作天內
價格
多形性膠質母細胞瘤治療(GBM)的全球市場 Glioblastoma Multiforme Treatment (GBM)
出版日期: 2021年04月01日內容資訊: 英文 129 Pages
簡介

全球多形性膠質母細胞瘤治療(GBM)的市場規模,預計在分析期間(2020年∼2027年)將以10%的年複合成長率增長,從2020年的4億9,330萬美元,到2027年達到9億6,330萬美元。

本報告所分析的市場區隔之一的Bevacizumab(Avastin)部門,分析期間中預計將以10.8%的年複合成長率增長,達到3億3,780萬美元。

本報告提供全球多形性膠質母細胞瘤治療(GBM)市場的相關調查,提供市場佔有率,Covid-19的影響,趨勢和成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • Amneal Pharmaceuticals LLC
  • Arbor Pharmaceuticals LLC
  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

目錄

I. 調查手法

II. 摘要整理

  • 市場概要
    • 影響者市場洞察
    • 全球市場的軌跡
    • Covid-19的影響與即將到來的全球景氣衰退
  • 主要企業
  • 趨勢與推動要素
  • 全球市場預測

III. 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 其他地區

IV. 競爭

  • 企業簡介:42公司

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP16434

Abstract:

Global Glioblastoma Multiforme Treatment (GBM) Market to Reach $963.3 Million by 2027

Amid the COVID-19 crisis, the global market for Glioblastoma Multiforme Treatment (GBM) estimated at US$493.3 Million in the year 2020, is projected to reach a revised size of US$963.3 Million by 2027, growing at a CAGR of 10% over the analysis period 2020-2027. Bevacizumab (Avastin), one of the segments analyzed in the report, is projected to record a 10.8% CAGR and reach US$337.8 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Temozolomide (Temodar and Temodal and Temcad) segment is readjusted to a revised 9.9% CAGR for the next 7-year period.

The U.S. Market is Estimated at $146.4 Million, While China is Forecast to Grow at 9.4% CAGR

The Glioblastoma Multiforme Treatment (GBM) market in the U.S. is estimated at US$146.4 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$165.9 Million by the year 2027 trailing a CAGR of 9.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 9.3% and 8.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.1% CAGR.

Carmustine (BiCNU) Segment to Record 8.8% CAGR

In the global Carmustine (BiCNU) segment, USA, Canada, Japan, China and Europe will drive the 8.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$52.2 Million in the year 2020 will reach a projected size of US$94.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$111.3 Million by the year 2027.

Select Competitors (Total 42 Featured) -

  • Amneal Pharmaceuticals LLC
  • Arbor Pharmaceuticals LLC
  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Glioblastoma Multiforme Treatment (GBM) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Bevacizumab (Avastin) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Bevacizumab (Avastin) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Bevacizumab (Avastin) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Temozolomide (Temodar and Temodal and Temcad) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Temozolomide (Temodar and Temodal and Temcad) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Temozolomide (Temodar and Temodal and Temcad) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Carmustine (BiCNU) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Carmustine (BiCNU) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Carmustine (BiCNU) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 13: USA Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 14: USA Historic Review for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 15: USA 15-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Drug - Percentage Breakdown of Value Sales for Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 16: Canada Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 17: Canada Historic Review for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 18: Canada 15-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Drug - Percentage Breakdown of Value Sales for Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 19: Japan Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 20: Japan Historic Review for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 21: Japan 15-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Drug - Percentage Breakdown of Value Sales for Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 22: China Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 23: China Historic Review for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 24: China 15-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Drug - Percentage Breakdown of Value Sales for Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 25: Europe Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 26: Europe Historic Review for Glioblastoma Multiforme Treatment (GBM) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 27: Europe 15-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 28: Europe Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 29: Europe Historic Review for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 30: Europe 15-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Drug - Percentage Breakdown of Value Sales for Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 31: France Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 32: France Historic Review for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 33: France 15-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Drug - Percentage Breakdown of Value Sales for Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 34: Germany Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 35: Germany Historic Review for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 36: Germany 15-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Drug - Percentage Breakdown of Value Sales for Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 37: Italy Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Italy Historic Review for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 39: Italy 15-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Drug - Percentage Breakdown of Value Sales for Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 40: UK Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 41: UK Historic Review for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 42: UK 15-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Drug - Percentage Breakdown of Value Sales for Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 43: Rest of Europe Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Rest of Europe Historic Review for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 45: Rest of Europe 15-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Drug - Percentage Breakdown of Value Sales for Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 46: Asia-Pacific Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Asia-Pacific Historic Review for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 48: Asia-Pacific 15-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Drug - Percentage Breakdown of Value Sales for Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 49: Rest of World Current & Future Analysis for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Rest of World Historic Review for Glioblastoma Multiforme Treatment (GBM) by Drug - Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
    • TABLE 51: Rest of World 15-Year Perspective for Glioblastoma Multiforme Treatment (GBM) by Drug - Percentage Breakdown of Value Sales for Bevacizumab (Avastin), Temozolomide (Temodar and Temodal and Temcad) and Carmustine (BiCNU) for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 42